PMG Research, Inc | PMG Research of Charleston
Status and phase
Conditions
Treatments
About
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Full description
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
825 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
US GSK Clinical Trials call Center; EU GSK Clinical Trials Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal